BlackRock’s Achilles Therapeutics ACHL Stock Holding History

BlackRock’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-253,112	Closed	-$572K	–	5861
2022 Q3	$572K	Sell	253,112 -7,291	-3%	-$20.6K	﹤0.01%	4680
2022 Q2	$656K	Sell	260,403 -6,254	-2%	-$15.4K	﹤0.01%	4683
2022 Q1	$784K	Buy	266,657 +54,225	+26%	+$193K	﹤0.01%	4747
2021 Q4	$1.06M	Buy	+212,432	New	+$1.29M	﹤0.01%	4644
2021 Q3	–	Sell	-25,000	Closed	-$244K	–	5710
2021 Q2	$244K	Hold	25,000	–	–	﹤0.01%	4858
2021 Q1	$413K	Buy	+25,000	New	+$414K	﹤0.01%	4635

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock's ACHL Position: Q4 2022 in Review

BlackRock sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 253,112 shares — an estimated $572K sold.

BlackRock first reported a position in ACHL in Q1 2021 and held it in 6 quarters. The position peaked at $1.06M in Q4 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

BlackRock reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
BlackRock sold 253,112 Achilles Therapeutics shares in Q4 2022, an estimated $572K.
BlackRock first reported a position in Achilles Therapeutics in Q1 2021 and held it in 6 quarters.
BlackRock's Achilles Therapeutics position peaked at $1.06M in Q4 2021.
23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.